Menu
×
West Ashley Library
9 a.m. - 7 p.m.
Phone: (843) 766-6635
Folly Beach Library
9 a.m. - 5:30 p.m.
Phone: (843) 588-2001
Edgar Allan Poe/Sullivan's Island Library
Closed for renovations
Phone: (843) 883-3914
Wando Mount Pleasant Library
9 a.m. - 8 p.m.
Phone: (843) 805-6888
Village Library
9 a.m. - 6 p.m.
Phone: (843) 884-9741
St. Paul's/Hollywood Library
9 a.m. - 8 p.m.
Phone: (843) 889-3300
Otranto Road Library
9 a.m. - 8 p.m.
Phone: (843) 572-4094
Mt. Pleasant Library
9 a.m. - 8 p.m.
Phone: (843) 849-6161
McClellanville Library
9 a.m. - 6 p.m.
Phone: (843) 887-3699
Keith Summey North Charleston Library
9 a.m. - 8 p.m.
Phone: (843) 744-2489
John's Island Library
9 a.m. - 8 p.m.
Phone: (843) 559-1945
Hurd/St. Andrews Library
9 a.m. - 8 p.m.
Phone: (843) 766-2546
Miss Jane's Building (Edisto Library Temporary Location)
9 a.m. - 4 p.m.
Phone: (843) 869-2355
Dorchester Road Library
9 a.m. - 8 p.m.
Phone: (843) 552-6466
John L. Dart Library
9 a.m. - 7 p.m.
Phone: (843) 722-7550
Baxter-Patrick James Island
9 a.m. - 8 p.m.
Phone: (843) 795-6679
Main Library
9 a.m. - 8 p.m.
Phone: (843) 805-6930
Bees Ferry West Ashley Library
9 a.m. - 8 p.m.
Phone: (843) 805-6892
Mobile Library
9 a.m. - 5 p.m.
Phone: (843) 805-6909
Today's Hours
West Ashley Library
9 a.m. - 7 p.m.
Phone: (843) 766-6635
Folly Beach Library
9 a.m. - 5:30 p.m.
Phone: (843) 588-2001
Edgar Allan Poe/Sullivan's Island Library
Closed for renovations
Phone: (843) 883-3914
Wando Mount Pleasant Library
9 a.m. - 8 p.m.
Phone: (843) 805-6888
Village Library
9 a.m. - 6 p.m.
Phone: (843) 884-9741
St. Paul's/Hollywood Library
9 a.m. - 8 p.m.
Phone: (843) 889-3300
Otranto Road Library
9 a.m. - 8 p.m.
Phone: (843) 572-4094
Mt. Pleasant Library
9 a.m. - 8 p.m.
Phone: (843) 849-6161
McClellanville Library
9 a.m. - 6 p.m.
Phone: (843) 887-3699
Keith Summey North Charleston Library
9 a.m. - 8 p.m.
Phone: (843) 744-2489
John's Island Library
9 a.m. - 8 p.m.
Phone: (843) 559-1945
Hurd/St. Andrews Library
9 a.m. - 8 p.m.
Phone: (843) 766-2546
Miss Jane's Building (Edisto Library Temporary Location)
9 a.m. - 4 p.m.
Phone: (843) 869-2355
Dorchester Road Library
9 a.m. - 8 p.m.
Phone: (843) 552-6466
John L. Dart Library
9 a.m. - 7 p.m.
Phone: (843) 722-7550
Baxter-Patrick James Island
9 a.m. - 8 p.m.
Phone: (843) 795-6679
Main Library
9 a.m. - 8 p.m.
Phone: (843) 805-6930
Bees Ferry West Ashley Library
9 a.m. - 8 p.m.
Phone: (843) 805-6892
Mobile Library
9 a.m. - 5 p.m.
Phone: (843) 805-6909
Patron Login
menu
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
- Author(s): Kohsaka S;Kohsaka S; Lam CSP; Lam CSP; Lam CSP; Lam CSP; Kim DJ; Kim DJ; Cavender MA; Cavender MA; Norhammar A; Norhammar A; Jørgensen ME; Jørgensen ME; Jørgensen ME; Birkeland KI; Birkeland KI; Holl RW; Holl RW; Franch-Nadal J; Franch-Nadal J; Tangri N; Tangri N; Shaw JE; Shaw JE; Ilomäki J; Ilomäki J; Karasik A; Karasik A; Goh SY; Goh SY; Chiang CE; Chiang CE; Chiang CE; Thuresson M; Thuresson M; Chen H; Chen H; Wittbrodt E; Wittbrodt E; Bodegård J; Bodegård J; Surmont F; Surmont F; Fenici P; Fenici P; Kosiborod M; Kosiborod M; Kosiborod M; Kosiborod M; Kosiborod M
- Source:
The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2020 Jul; Vol. 8 (7), pp. 606-615.- Publication Type:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't- Language:
English - Source:
- Additional Information
- Corporate Authors:
- Source: Publisher: The Lancet, Diabetes & Endocrinology Country of Publication: England NLM ID: 101618821 Publication Model: Print Cited Medium: Internet ISSN: 2213-8595 (Electronic) Linking ISSN: 22138587 NLM ISO Abbreviation: Lancet Diabetes Endocrinol Subsets: MEDLINE
- Publication Information: Original Publication: London : The Lancet, Diabetes & Endocrinology, [2013]-
- Subject Terms: Biomarkers/*analysis ; Cardiovascular Diseases/*mortality ; Diabetes Mellitus, Type 2/*mortality ; Dipeptidyl-Peptidase IV Inhibitors/*adverse effects ; Sodium-Glucose Transporter 2 Inhibitors/*adverse effects; Blood Glucose/analysis ; Cardiovascular Diseases/chemically induced ; Cardiovascular Diseases/diagnosis ; Cohort Studies ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/pathology ; Female ; Follow-Up Studies ; Humans ; International Agencies ; Male ; Middle Aged ; Prognosis ; Risk Factors ; Survival Rate
- Abstract: Background: Cardiovascular outcome trials have shown cardiovascular benefit with sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors have not shown an effect. We aimed to address knowledge gaps regarding the comparative effectiveness of SGLT2 inhibitor use in clinical practice (with DPP-4 inhibitor use as an active comparator) across a range of cardiovascular risks and in diverse geographical settings.
Methods: In this comparative cohort study, we used data from clinical practice from 13 countries in the Asia-Pacific, Middle East, European, and North American regions to assess the risk of cardiovascular events and death in adult patients with type 2 diabetes newly initiated on SGLT2 inhibitors compared with those newly initiated on DPP-4 inhibitors. De-identified health records were used to select patients who were initiated on these drug classes between Dec 1, 2012, and May 1, 2016, with follow-up until Dec 31, 2014, to Nov 30, 2017 (full range; dates varied by country). Non-parsimonious propensity scores for SGLT2 inhibitor initiation were developed for each country and patients who were initiated on an SGLT2 inhibitor were matched with those who were initiated on a DPP-4 inhibitor in a 1:1 ratio. Outcomes assessed were hospitalisation for heart failure, all-cause death, myocardial infarction, and stroke. Hazard ratios (HRs) were estimated by country and then pooled in a weighted meta-analysis.
Findings: Following propensity score matching, 193 124 new users of SGLT2 inhibitors and 193 124 new users of DPP-4 inhibitors were included in the study population. Participants had a mean age of 58 years (SD 12·2), 170 335 (44·1%) of 386 248 were women, and 111 933 (30·1%) of 372 262 had established cardiovascular disease. Initiation of an SGLT2 inhibitor versus a DPP-4 inhibitor was associated with substantially lower risks of hospitalisation for heart failure (HR 0·69, 95% CI 0·61-0·77; p<0·0001), all-cause death (0·59, 0·52-0·67; p<0·0001), and the composite of hospitalisation for heart failure or all-cause death (0·64, 0·57-0·72; p<0·0001). Risks of myocardial infarction (HR 0·88, 0·80-0·98; p=0·020) and stroke (0·85 0·77-0·93; p=0·0004) were significantly but modestly lower with SGLT2 inhibitors versus DPP-4 inhibitors.
Interpretation: In this large, international, observational study, initiation of SGLT2 inhibitors versus DPP-4 inhibitors was associated with lower risks of heart failure, death, myocardial infarction, and stroke, providing further support for the cardiovascular benefits associated with use of SGLT2 inhibitors in patients with type 2 diabetes.
Funding: AstraZeneca.
(Copyright © 2020 Elsevier Ltd. All rights reserved.) - Comments: Comment in: Lancet Diabetes Endocrinol. 2020 Jul;8(7):557-558. (PMID: 32559467)
- Contributed Indexing: Investigator: M Kosiborod; MA Cavender; JP Wilding; K Khunti; A Norhammar; K Birkeland; ME Jørgensen; RW Holl; CS Lam; HL Gulseth; B Carstensen; E Bollow; J Franch-Nadal; LA García Rodríguez; A Karasik; N Tangri; S Kohsaka; DJ Kim; J Shaw; S Arnold; SY Goh; P Fenici; J Bodegård; H Chen; F Surmont; BT Blak; ET Wittbrodt; M Saathoff; Y Noguchi; D Tan; M Williams; HW Lee; M Greenbloom; O Kaidanovich-Beilin; KK Yeo; YM Bee; J Khoo; A Koong; YH Lau; F Gao; WB Tan; HA Kadir; KH Ha; J Lee; G Chodick; C Melzer-Cohen; R Whitlock; L Cea-Soriano; OF Cantero; JA Menzin; M Guthrie; J Ilomaki; D Magliano
- Accession Number: 0 (Biomarkers)
0 (Blood Glucose)
0 (Dipeptidyl-Peptidase IV Inhibitors)
0 (Sodium-Glucose Transporter 2 Inhibitors) - Publication Date: Date Created: 20200620 Date Completed: 20200720 Latest Revision: 20210920
- Publication Date: 20221213
- Accession Number: 10.1016/S2213-8587(20)30130-3
- Accession Number: 32559476
Contact CCPL
Copyright 2022 Charleston County Public Library Powered By EBSCO Stacks 3.3.0 [350.3] | Staff Login
No Comments.